Altrius Capital Management Inc raised its holdings in Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 3.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 189,993 shares of the company's stock after buying an additional 6,545 shares during the quarter. Roche comprises 1.9% of Altrius Capital Management Inc's holdings, making the stock its 21st largest position. Altrius Capital Management Inc's holdings in Roche were worth $7,818,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RHHBY. SVB Wealth LLC purchased a new stake in Roche in the fourth quarter valued at about $555,000. HighPoint Advisor Group LLC raised its stake in Roche by 2.8% in the fourth quarter. HighPoint Advisor Group LLC now owns 11,091 shares of the company's stock valued at $387,000 after buying an additional 304 shares during the last quarter. Hancock Whitney Corp raised its stake in Roche by 6.8% in the fourth quarter. Hancock Whitney Corp now owns 23,516 shares of the company's stock valued at $820,000 after buying an additional 1,496 shares during the last quarter. Minot DeBlois Advisors LLC purchased a new position in shares of Roche in the fourth quarter worth about $752,000. Finally, Confluence Investment Management LLC raised its stake in shares of Roche by 3.6% in the first quarter. Confluence Investment Management LLC now owns 14,491 shares of the company's stock worth $596,000 after purchasing an additional 510 shares during the last quarter.
Roche Price Performance
RHHBY traded up $0.84 during trading on Monday, hitting $40.04. The company's stock had a trading volume of 1,501,040 shares, compared to its average volume of 1,094,993. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 0.85. Roche Holding AG has a twelve month low of $33.76 and a twelve month high of $44.31. The business's fifty day simple moving average is $39.75 and its 200 day simple moving average is $39.21.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on RHHBY. HSBC cut Roche from a "buy" rating to a "hold" rating in a research note on Monday, April 28th. Hsbc Global Res lowered Roche from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, one has given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Roche presently has a consensus rating of "Moderate Buy".
Read Our Latest Stock Report on Roche
Roche Company Profile
(
Free Report)
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Featured Stories

Before you consider Roche, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roche wasn't on the list.
While Roche currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.